Immunity to Cancer
eBook - PDF

Immunity to Cancer

  1. 678 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

Immunity to Cancer

About this book

Immunity to Cancer documents the proceedings of a conference on ""Immunity to Cancer"" held at Williamsburg, Virginia, September 10-12, 1984. This was the first open conference since the New York Academy of Sciences meeting in 1975 that attempted to address the entire range of topics encompassed by tumor immunology and immunotherapy. The papers presented in this volume were invited from experts in diverse areas of tumor immunology and closely related subjects. There was an attempt to proceed logically from a consideration of the antigenicity of tumors and the use of monoclonal antibodies to examine specific antigens, to a review of regulatory and effector mechanisms. Immunological approaches to therapy were then considered systematically, both for classical modes of immunotherapy and for the newly expanded categories of biological response modifiers or biomodulators. Also included were papers on vaccination against cancer and on the analogy between the strategies for chemotherapy and immunotherapy.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Immunity to Cancer by Arnold Reif in PDF and/or ePUB format, as well as other popular books in Medicine & Diseases & Allergies. We have over one million books available in our catalogue for you to explore.

Information

Publisher
Academic Press
Year
2012
Print ISBN
9780125862707
eBook ISBN
9780323143561
Topic
Medicine
Subtopic
Diseases & Allergies

Table of contents

  1. Front Cover
  2. Immunity to Cancer
  3. Copyright Page
  4. Table of Content
  5. Senior Authors
  6. Preface
  7. Acknowledgments
  8. SECTION 1 - IDENTIFICATION AND CHARACTERIZATION OF TUMOR ANTIGENS
  9. Chapter 1 - SOME KEY PROBLEMS FOR SUCCESS OF CLASSICAL IMMUNOTHERAPY
  10. Chapter 2 - WHAT ARE TUMOR ANTIGENS?
  11. Chapter 3 - ANTIGENICITY OF SIMIAN VIRUS 40 TRANSFORMED CELLS
  12. Chapter 4 - CHARACTERISTICS OF TUMOR ANTIGENS ON TUMORS INDUCED BY CHEMICAL CARCINOGENS. SOME RECENT FINDINGS
  13. Chapter 5 - IMMUNOBIOLOGY OF RAW117 LARGE CELL LYMPHOMA
  14. Chapter 6 - BIOCHEMICAL AND FUNCTIONAL PROFILES OF TWO UNIQUE MELANOMA ASSOCIATED ANTIGENS
  15. Chapter 7 - IDENTIFICATION AND CHARACTERIZATION OF HUMAN LEUKEMIA ASSOCIATED ANTIGENS
  16. Chapter 8 - MONOCLONAL ANTIBODIES AGAINST GASTRO -INTESTINAL TUMOR ASSOCIATED ANTIGENS
  17. Chapter 9 - IMMUNODIAGNOSIS OF MALIGNANCY WITH MONOCLONAL ANTIBODIES TO CELL SURFACE ANTIGENS EXPRESSED BY NON-NEOPLASTIC CELLS
  18. Chapter 10 - HUMAN MONOCLONAL ANTIBODIES THAT DISTINGUISH CUTANEOUS MELANOMAS FROM BENIGN NEVI IN FIXED SECTIONS
  19. Scetion 2 - IMMUNE RESPONSES TO TUMOR ANTIGENS
  20. Chapter 11 - HOST RESPONSE TO EPSTEIN – BARR VIRUS INEECTED B CELLS
  21. Chapter 12 - THE ROLE OF T LYMPHOCYTE SUBSETS IN THE REJECTION OF 3-METHYLCHOLANTHRENE INDUCED RAT SARCOMA Mc7
  22. Chapter 13 - THE HUMORAL IMMUNE RESPONSE TO HUMAN CANCER
  23. Chapter 14 RELEVANCE OF TUMOR MODEL ANTIGENICITIES TO HUMAN TUMOR IMMUNOLOGY
  24. Chapter 15 - INTENSIFICATION OF TUMOR ANTIGENICITY
  25. Chapter 16 - EFFECTOR CELLS OF T CELL LINEAGE
  26. Chapter 17- MACROPHAGE EFFECTOR AND REGULATORY FUNCTIONS
  27. Chapter 18 - NATURAL KILLER (NK) CELLS: CHARACTERISTICS AND POSSIBLE ROLE IN RESISTANCE AGAINST TUMOR GROWTH
  28. Chapter 19 - UV LIGHT-INDUCED INCREASE IN IMMUNOGENICITY OF 3LL TUMOR CELLS
  29. Section 3 - REGULATION OF THE IMMUNE RESPONSE TO TUMOR CELLS
  30. Chapter 20 - SUPPRESSOR CELLS: T CELLS AND MACROPHAGES
  31. Chapter 21 - IDIOTYPES AND ANTI-IDIOTYPES
  32. Chapter 22 - HUMAN T-T CELL INTERACTIONS
  33. Chapter 23 - LYMPHOKINES AS REGULATORS OF TUMOR CELL FUNCTION
  34. Chapter 24 - INTERFERONS : CYTOSTATIC AND IMMUNOMODULATORY EFFECTS
  35. Chapter 25 - POSSIBLE ROLE OF IRON DEPLETION AS CAUSE OF TUMOR CELL CYTOTOXICITY INDUCED BY ACTIVATED MACROPHAGES
  36. Chapter 26 - IMMUNOLOGICAL SURVEILLANCE REVISITED
  37. Chapter 27 - AIDS and KAPOSI SARCOMA
  38. Chapter 28 - GENETICS AND IMMUNOLOGY OF THE P815-X2 MODEL
  39. Chapter 29 - SHED MEMBRANE VESICLES: A MECHANISM FOR TUMOR-INDUCED IMMUNOSUPPRESSION
  40. Chapter 30 - MODIFICATION OF THE INDUCTION OF BCGcw SUPPRESSOR CELLS BY MITOMYCIN C-1
  41. Chapter 31 - IMMUNOMODULATION BY A LOW DOSE OF CYCLOPHOSPHAMIDE AS THE PRIMARY MECHANISM FOR THE CURE OF MICE BEARING A LARGE METASTATIC MOPC-315 TUMOR
  42. Chapter 32 - AN IMMUNOTHERAPEUTIC MODEL FOR MURINE TRANSITIONAL CELL CARCINOMAS
  43. Chapter 33 - REGULATION OF HUMAN T CELL RESPONSES BY GAMMA INTERFERON (IFN-γ): STUDIES ON THE BINDING AND BIOLOGICAL EFFECTS OF IFN-γ ON DISTINCT T CELL SUBPOPULATIONS
  44. Scetion 4 - IMMUNOTHERAPY AND BIOMODULATORS
  45. Chapter 34 - BIOMODULATION: A CLASSIFICATION AND OVERVIEW
  46. Chapter 35 - ACTIVE SPECIFIC IMMUNOTHERAPY WITH EXTRACTED TUMOR-SPECIFIC TRANSPLANTATION ANTIGENS
  47. Chapter 36 - ACTIVE SPECIFIC IMMUNOTHERAPY AS AN ADJUNCT TO THE TREATMENT OF METASTATIC SOLID TUMORS
  48. Chapter 37 - CURRENT STATUS OF ACTIVE NON-SPECIFIC IMMUNOTHERAPY
  49. Chapter 38 - ADOPTIVE CELLULAR IMMUNOTHERAPY
  50. Chapter 39 - THYMOSINS IN THE TREATMENT OF CANCER
  51. Chapter 40 - RESTORATIVE IMMUNOTHERAPY WITH INTERLEUKIN 2
  52. Chapter 41 - STAPHYLOCOCCAL PROTEIN A COLUMN: ITS MECHANISM OF ACTION
  53. Chapter 42 - MATURATIONAL FACTORS IN MYELOID LEUKEMIA
  54. Chapter 43 - In Vitro and In Vivo Stimulation of Murine Lymphocytes by Human Recombinant Interleuki n 2
  55. Chapter 44 - CHEMO-ADOPTIVE IMMUNOTHERAPY OF MICE WITH ESTABLISHED CARCINOMAS USING INTERLEUKIN-2-PROPAGATED LYMPHOCYTES AND CRUDE LYMPHOKINE PREPARATIONS
  56. Scetion 5 - IMMUNOTHERAPY AND IMMUNOPROPHYLAXIS
  57. Chapter 45 - MODULATION OF IMMUNE FUNCTIONS BY INTERFERONS
  58. Chapter 46 - PASSIVE IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES TO DIFFERENTIATION ANTIGENS
  59. Chapter 47 - Antibody – Drug and Antibody-Toxin Conjugates
  60. Chapter 48 - ANTIBODY-RADIOISOTOPE CONJUGATES FOR TUMOR LOCALIZATION AND TREATMENT
  61. Chapter 49 - VACCINATION AGAINST VIRALLY INDUCED ANIMAL TUMORS
  62. Chapter 50 - THE BIOLOGY OF HEPATITIS B VIRUS AND HEPATOCELLULAR CARCINOMA
  63. Chapter 51 - CHEMOIMMUNOTHERAPY — STRATEGY CONSIDERATIONS
  64. CONFERENCE SUMMARY
  65. INDEX